切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2022, Vol. 11 ›› Issue (02) : 182 -187. doi: 10.3877/cma.j.issn.2095-3232.2022.02.014

临床研究

肝移植术后长期存活患者生存情况单中心分析
李嘉伟1, 庄雅峰1, 王明2, 柯瑞盛3, 江艺4, 蔡秋程4,()   
  1. 1. 350025 福州,福建医科大学福总临床医学院;350025 福州,解放军联勤保障部队第九〇〇医院肝胆外科
    2. 350025 福州,解放军联勤保障部队第九〇〇医院肝胆外科;350025 福州,厦门大学附属东方医院普通外科
    3. 361001 厦门,厦门大学附属第一医院普通外科
    4. 350025 福州,解放军联勤保障部队第九〇〇医院肝胆外科
  • 收稿日期:2021-12-01 出版日期:2022-04-10
  • 通信作者: 蔡秋程
  • 基金资助:
    福建省自然科学基金(2020Y0078); 福建省自然科学基金青年创新项目(2020J05299); 厦门市医疗卫生指导性课题项目(3502Z20209011)

Survival of long-term survivors after liver transplantation: a single-center analysis

Jiawei Li1, Yafeng Zhuang1, Ming Wang2, Ruisheng Ke3, Yi Jiang4, Qiucheng Cai4,()   

  1. 1. Clinical Medical College, Fuzhou General Hospital of Fujian Medical University, Fuzhou 350025, China; Department of Hepatobiliary Surgery, the 900th Hospital of Joint Logistics Support Force of Chinese PLA, Fuzhou 350025, China
    2. Department of Hepatobiliary Surgery, the 900th Hospital of Joint Logistics Support Force of Chinese PLA, Fuzhou 350025, China; Department of General Surgery, Dongfang Hospital Affiliated to Xiamen University, Fuzhou 350025, China
    3. Department of General Surgery, the First Affiliated Hospital of Xiamen University, Xiamen 361001, China
    4. Department of Hepatobiliary Surgery, the 900th Hospital of Joint Logistics Support Force of Chinese PLA, Fuzhou 350025, China
  • Received:2021-12-01 Published:2022-04-10
  • Corresponding author: Qiucheng Cai
引用本文:

李嘉伟, 庄雅峰, 王明, 柯瑞盛, 江艺, 蔡秋程. 肝移植术后长期存活患者生存情况单中心分析[J/OL]. 中华肝脏外科手术学电子杂志, 2022, 11(02): 182-187.

Jiawei Li, Yafeng Zhuang, Ming Wang, Ruisheng Ke, Yi Jiang, Qiucheng Cai. Survival of long-term survivors after liver transplantation: a single-center analysis[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2022, 11(02): 182-187.

目的

探讨肝移植术后长期存活(生存时间≥10年)患者生存情况。

方法

回顾性分析2005年1月至2010年12月解放军联勤保障部队第九○○医院行肝移植术后长期存活的104例患者临床资料。其中男91例,女13例;年龄15~71岁,中位年龄45岁。术前HBsAg阳性77例,阴性27例。患者均签署知情同意书,符合医学伦理学规定。观察患者肝移植术后胆道并发症、恶性肿瘤新发或复发、乙型病毒性肝炎(乙肝)新发或复发、感染、肾功能损害、代谢性并发症、心脑血管并发症、排斥反应等发生情况及死因。

结果

肝移植术后长期存活占同期手术患者的46.0%(104/226),其中原发性肝癌30例、胆管癌3例、肝衰竭64例、肝豆状核变性7例。随访时间120~191个月,中位随访时间142个月。随访期间胆道并发症10例,肿瘤复发5例、新发9例,乙肝复发6例、新发5例,肺部感染15例,结核感染5例,肾功能损害22例,高血压病34例,糖尿病31例,高脂血症29例,冠状动脉粥样硬化性心脏病7例,排斥反应18例。随访期间死亡6例,死于肺部感染3例,恶性肿瘤新发和(或)复发2例,慢性排斥反应1例。

结论

术后胆道并发症、恶性肿瘤及乙肝新发和复发、感染、肾功能损害、代谢性并发症、心脑血管并发症、排斥反应等对肝移植患者术后长期存活有重要影响,肺部感染、恶性肿瘤新发和复发是主要死因。

Objective

To investigate the long-term survival (survival time of ≥10 years) of the recipients after liver transplantation.

Methods

Clinical data of 104 patients who achieved long-term survival after liver transplantation in the 900th Hospital of Joint Logistics Support Force of Chinese PLA from January 2005 to December 2010 were retrospectively analyzed. Among them, 91 patients were male and 13 female,aged from 15 to 71 years, with a median age of 45 years. Prior to liver transplantation, 77 cases were positive and 27 cases were negative for HBsAg. The informed consents of all patients were obtained and the local ethical committee approval was received. The incidence of biliary complications, de novo or recurrent malignant tumors, de novo or recurrent hepatitis B virus infection (hepatitis B), infection, renal function damage, metabolic complications, cardio-cerebrovascular complications, rejections and causes of death after liver transplantation were observed.

Results

The long-term survival rate after liver transplantation was 46.0%(104/226), including 30 cases of primary liver cancer, 3 cases of cholangiocarcinoma, 64 cases of liver failure and 7 cases of hepatolenticular degeneration. Postoperative follow-up time was ranged from 120 to191 months, with a median of 142 months. During the postoperative follow-up, 10 cases of biliary complications, 5 recipients developed malignant tumor recurrence, 9 cases of de novo tumors, 6 cases of recurrent hepatitis B, 5 cases of de novo hepatitis B, 15 cases of pulmonary infection, 5 cases of tuberculosis infection, 22 cases of renal function damage, 34 cases of hypertension, 31 cases of diabetes mellitus, 29 cases of hyperlipidemia, 7 cases of coronary atherosclerotic heart disease and 18 cases of rejections. 6 recipients died during follow-up, including 3 cases of pulmonary infection, 2 cases of de novo and/or recurrent malignant tumors and 1 case of chronic rejection.

Conclusions

Postoperative biliary complications, de novo and recurrent of malignant tumors and hepatitis B, infection, renal function damage, metabolic complications, cardio-cerebrovascular complications, rejections exert significant effects upon the long-term survival of the recipients after liver transplantation. Pulmonary infection, de novo and recurrent malignant tumors are the major causes of death.

表1 104肝移植术后长期存活患者并发症情况
[1]
中华医学会器官移植学分会. 器官移植术后乙型肝炎病毒感染诊疗规范(2019版)[J/CD]. 实用器官移植电子杂志, 2020, 8(2):81-85.
[2]
中国医师协会器官移植医师分会,中华医学会器官移植学分会肝移植学组. 中国肝移植受者肾损伤管理专家共识(2017版)[J]. 中华消化外科杂志, 2017, 16(4):319-326.
[3]
李新宇,黄磊,朱继业, 等. 肝移植术后生存10年及以上患者远期并发症随访分析[J]. 中华全科医师杂志, 2019, 18(4):347-351.
[4]
吕少诚,潘冰,李立新, 等. 不同肝癌肝移植标准受者预后分析[J/CD]. 中华移植杂志(电子版), 2019, 13(3):206-209.
[5]
Umeshita K, Eguchi S, Egawa H, et al. Liver transplantation in Japan: registry by the Japanese Liver Transplantation Society[J]. Hepatol Res, 2019, 49(9):964-980.
[6]
王垒,范林,彭贵主, 等. 经胆囊管胆道引流在肝移植胆道并发症预防和治疗中的应用[J/CD]. 实用器官移植电子杂志, 2017, 5(1):52-55.
[7]
中华医学会器官移植学分会. 中国肝移植术后并发症诊疗规范(2019版)[J]. 器官移植, 2021, 12(2):129-133.
[8]
蔡云石,刘雄威,肖衡, 等. 肝移植术后胆道并发症的诊治[J/CD]. 中华肝脏外科手术学电子杂志, 2018, 7(5):391-395.
[9]
李名安,吴春,罗骏阳, 等. 经皮介入治疗在肝移植术后胆道并发症中的应用探讨[J]. 中华器官移植杂志, 2017, 38(3):165-171.
[10]
蔡秋程,杨芳,张小进, 等. 肝移植5年后生存影响因素分析[J]. 肝胆外科杂志, 2013, 21(3):174-176.
[11]
方程,严盛,郑树森. 肝移植术后胆道并发症的影响因素及诊治进展[J]. 中华普通外科杂志, 2014, 29(6):486-488.
[12]
Fujiki M, Hashimoto K, Palaios E, et al. Probability, management, and long-term outcomes of biliary complications after hepatic artery thrombosis in liver transplant recipients[J]. Surgery, 2017, 162(5):1101-1111.
[13]
Dumortier J, Chambon-Augoyard C, Guillaud O, et al. Anastomotic bilio-biliary stricture after adult liver transplantation: a retrospective study over 20 years in a single center[J]. Clin Res Hepatol Gastroenterol, 2020, 44(4):564-571.
[14]
李彦杰,马毅,郭志勇, 等. 肝癌肝移植术后复发和转移特点及预后因素分析[J]. 中国实用外科杂志, 2012, 32(8):655-658.
[15]
郑树森,程启阳,耿磊, 等. 肝癌肝移植术后肝癌复发研究新进展[J]. 中国普通外科杂志, 2019, 28(7):773-778.
[16]
Vivarelli M, Cucchetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence[J]. Ann Surg, 2008, 248(5):857-862.
[17]
陈凯,王唑,史政荣. 肝移植术后肿瘤复发与免疫抑制剂的关系[J]. 中华肝胆外科杂志2021, 27(3):192-196.
[18]
刘少儒,许磊波. 肝癌肝移植术后复发转移的免疫治疗[J]. 器官移植, 2021, 12(3):272-279.
[19]
李照,朱继业. 免疫治疗时代下的肝癌肝移植[J]. 临床肝胆病杂志, 2021, 37(2):249-252.
[20]
Fung J, Wong T, Chok K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years[J]. Hepatology, 2017, 66(4):1036-1044.
[21]
Ueda Y, Marusawa H, Kaido T, et al. Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation[J]. Hepatol Res, 2013, 43(1):67-71.
[22]
Katz LH, Paul M, Guy DG, et al. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? systematic review and meta-analysis[J]. Transpl Infect Dis, 2010, 12(4):292-308.
[23]
中国医师协会器官移植医师分会,中华医学会器官移植学分会肝移植学组. 中国肝移植受者代谢病管理专家共识(2019版)[J]. 器官移植, 2020, 11(1):19-29.
[24]
中华医学会器官移植学分会. 中国移植后糖尿病诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(1):1-9.
[25]
中华医学会器官移植学分会. 中国实体器官移植术后高血压诊疗规范(2019版)[J]. 器官移植, 2019, 10(2):112-121.
[26]
Aibara N, Ohyama K, Hidaka M, et al. Immune complexome analysis of antigens in circulating immune complexes from patients with acute cellular rejection after living donor liver transplantation[J]. Transpl Immunol, 2018(48):60-64.
[27]
中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J]. 器官移植, 2021, 12(1):8-14, 28.
[28]
Koo J, Wang HL. Acute, chronic, and humoral rejection: pathologic features under current immunosuppressive regimes[J]. Surg Pathol Clin, 2018, 11(2):431-452.
[1] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[3] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[4] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[5] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[6] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[7] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[8] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[9] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[10] 魏志鸿, 刘建勇, 吴小雅, 杨芳, 吕立志, 江艺, 蔡秋程. 肝移植术后急性移植物抗宿主病的诊治(附四例报告)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 846-851.
[11] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[12] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[13] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[14] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?